Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …

Abstract The French Headache Society proposes updated French guidelines for the
management of migraine. This article presents the second part of the guidelines, which is …

Migraine is the second most disabling disorder across all age groups worldwide. Since
2018, two classes of drugs that inhibit the actions of calcitonin gene-related peptide (CGRP) …

Background Controlled and real-world evidence have demonstrated the efficacy of
calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine …

Abstract Purpose of Review The authors present data on cardiovascular safety for the new
acute and preventive migraine treatments including ditans, gepants, and calcitonin gene …

Background Safety data on the use of migraine preventive monoclonal antibodies targeting
the calcitonin gene-related peptide (CGRP) system in pregnancy are limited. Methods …

Background Randomized clinical trials have demonstrated efficacy and safety of erenumab.
The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world …

Simple Summary In preclinical studies, it has been shown that the blockade of immune
checkpoint pathways increases the risk of fetal death. Therefore, the use of immune …

Objective To report a case of a woman who continued erenumab for migraine prophylaxis
throughout her pregnancy and to review the literature for pregnancy safety data for the …